EVOQ Partners With Gilead On NanoDisc Approach To RA, Lupus

03 Jan 2023

Michigan biotech follows 2021 collaboration in autoimmune disease with Amgen with its second tie-up, teaming up with Gilead in rheumatoid arthritis and systemic lupus erythematosus.

Nanotech — EVOQ's approach involves delivering antigens therapeutically via nanotechnology • Source: Shutterstock

Privately held EVOQ Therapeutics is using a new collaboration in autoimmune disease with Gilead Sciences, Inc., along with a similar partnership inked with Amgen, Inc., to get its NanoDisc delivery technology off the ground. During a 3 January interview to discuss the Gilead tie-up, CEO William Brinkerhoff said EVOQ saw substantial early potential for its platform in cancer but will now be looking at rheumatoid arthritis and systemic lupus erythematosus.

Launched in 2016 with intellectual property in-licensed from nearby University of Michigan, EVOQ uses a platform technology that takes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

26 Jun 2025

• By Kevin Grogan

The biotech had been looking at options to survive since May.

Kymera Inks CDK2 Deal With Gilead

25 Jun 2025

• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

24 Jun 2025

• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Stock Watch: When The Biotech Bandwagon Music Stops

24 Jun 2025

• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.